No public access
master's thesis
Value of galectin-3 and CA 125 in defining cardiomyopathy stages

Katarina Grdiša (2016)
University of Zagreb
Faculty of Pharmacy and Biochemistry
Department of medical biochemistry and haematology
Cite this document...

Grdiša, K. (2016). Vrijednost galektina-3 i CA 125 kod procjene stadija kardiomiopatija (Master's thesis). Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:164568

Grdiša, Katarina. "Vrijednost galektina-3 i CA 125 kod procjene stadija kardiomiopatija." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:164568

Grdiša, Katarina. "Vrijednost galektina-3 i CA 125 kod procjene stadija kardiomiopatija." Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, 2016. https://urn.nsk.hr/urn:nbn:hr:163:164568

Grdiša, K. (2016). 'Vrijednost galektina-3 i CA 125 kod procjene stadija kardiomiopatija', Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, accessed 18 August 2019, https://urn.nsk.hr/urn:nbn:hr:163:164568

Grdiša K. Vrijednost galektina-3 i CA 125 kod procjene stadija kardiomiopatija [Master's thesis]. Zagreb: University of Zagreb, Faculty of Pharmacy and Biochemistry; 2016 [cited 2019 August 18] Available at: https://urn.nsk.hr/urn:nbn:hr:163:164568

K. Grdiša, "Vrijednost galektina-3 i CA 125 kod procjene stadija kardiomiopatija", Master's thesis, University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, 2016. Available at: https://urn.nsk.hr/urn:nbn:hr:163:164568